Advances in Drug Development for Parkinson's Disease: Present Status

Publisher： Karger

E-ISSN： 1423-0313|93|5-6|260-271

ISSN： 0031-7012

Source： Pharmacology, Vol.93, Iss.5-6, 2014-08, pp. : 260-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Advances on the Neuroprotective Potential of Antioxidants in Experimental Models of Parkinson’s Disease

By Koppula Sushruta   Kumar Hemant   More Sandeep Vasant   Kim Byung Wook   Kim In Su   Choi Dong Kug  

International Journal of Molecular Sciences, Vol. 13, Iss. 8, 2012-08 ,pp. : 10608-10629

MDPI

Access to resources Recommend Favorite

Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers

By  

Pharmacology, Vol. 92, Iss. 3-4, 2013-10 ,pp. : 207-216

Karger

Access to resources Recommend Favorite

Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease

By Santiago Jose A.   Potashkin Judith A.  

Diagnostics, Vol. 4, Iss. 4, 2014-10 ,pp. : 153-164

MDPI

Access to resources Recommend Favorite

Advances in the Study of Heart Development and Disease Using Zebrafish

By Brown Daniel R.   Samsa Leigh Ann   Qian Li   Liu Jiandong  

Journal of Cardiovascular Development and Disease, Vol. 3, Iss. 2, 2016-04 ,pp. : 13-13

MDPI

Access to resources Recommend Favorite

Protein Kinases as Drug Development Targets for Heart Disease Therapy

By Dhalla Naranjan S.   Müller Alison L.  

Pharmaceuticals, Vol. 3, Iss. 7, 2010-07 ,pp. : 2111-2145

MDPI

Access to resources Recommend Favorite